Development of a New Fluorescent Agent for Intraoperative Image-Guided Breast Cancer Surgery
Development of a New Fluorescent Agent for Intraoperative Image-Guided Breast Cancer Surgery
批准号:
10132318
负责人:
Tohru Yamada
金额:
$35.26万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-01 至 2023-03-31
关键词:
3-DimensionalAddressAngiographyAnimal Cancer ModelAnimalsAppearanceBreast Cancer CellBreast Cancer TreatmentBreast-Conserving SurgeryCell Cycle ArrestCellsClinicClinicalClinical TrialsCoupledDataDetectionDevelopmentDiagnosticDiseaseEarly DiagnosisExcisionFDA approvedFluorescenceFluorescent DyesGoalsHepaticHumanImageImage-Guided SurgeryIonizing radiationKnowledgeLabelLeftLinkLocalized LesionLocationMagnetic Resonance ImagingMalignant NeoplasmsMammary NeoplasmsMammographyMediatingMethodsNear-infrared optical imagingNeoplasm MetastasisNoiseNoninfiltrating Intraductal CarcinomaNormal CellNormal tissue morphologyOncologyOperating RoomsOperative Surgical ProceduresPalpationPathologic ProcessesPatientsPeptidesPositioning AttributePre-Clinical ModelPrimary NeoplasmPrognosisProtocols documentationRecurrenceRepeat SurgeryResearchRiskSafetySignal TransductionStudy SectionSurgeonTP53 geneTechnologyTestingTherapeutic AgentsTimeTissuesTractionTransgenic MiceTransplantationTumor MarkersUltrasonographyVisualVisual PerceptionXenograft procedurebasecancer cellcancer surgerychemical conjugateclinical applicationclinical translationclinically relevantcontrast enhancedcost effectivedesigndetection limitexpectationflexibilityfluorescence imaginghigh resolution imagingimage guidedimaging agentimaging modalityimaging systemimprovedinstrumentmalignant breast neoplasmmolecular imagingmortalitymouse modelnoveloperationoptical imagingpatient derived xenograft modelpre-clinicalpreventstandard of caretargeted deliverytargeted imagingtooltumoruptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The precise surgical resection of breast cancer directly influences patient prognosis. However, it is often
difficult or impossible for surgeons to distinguish breast tumor from normal tissue during resection without
any intraoperative image guidance. Accurate identification of tumor margins and complete removal of the
tumor at the initial surgical operation will be of considerable help in a breast tumor operation.
Recently, optical imaging is gaining traction in the image-guided surgery field especially when coupled
with near infrared (NIR) fluorescence agent. NIR fluorescent image-guided surgery also affords surgeons
numerous advantages such as real-time detection with high-resolution image, and flexible instrument
without ionizing radiation. Furthermore, NIR imaging with addition of enhanced-contrast visualizes disease
prior to transection, and does not change the appearance of the surgical field of view. Indocyanin green
(ICG) is a NIR fluorescence agent and currently registered by the FDA for clinical applications, but not for
oncology. In order to use non-toxic ICG as an intraoperative tumor marker, development of a tumor-
targeting carrier is essential.
Many attempts have been made in the development of carrier molecules, in particular, cell-penetrating
peptides (CPPs) have shown to be a promising strategy for improving the delivery and intracellular uptake
of diagnostic and therapeutic agents. We have identified that a non-toxic CPP, p28, preferentially enters
and is retained significantly longer in breast cancer cells. We hypothesize that developing p28 as a
nontoxic tumor-targeting carrier for ICG will provide an ideal intraoperative imaging agent to clearly
distinguish tumor and surrounding normal tissue. Preliminary data with this new imaging molecule (p28
chemically conjugated to ICG, ICG-p28) support the hypothesis. We will take a strategic approach to test
our hypothesis in clinically relevant setting in multiple breast cancer animal models. It potentially provides
significant impact based on unique approach to prevent recurrence and consequently reduce risk of
metastatic disease and mortality.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1007/978-1-0716-1811-0_45
发表时间:
2022
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Naffouje S, Goto M, Ryoo I, Green A, Das Gupta TK, Yamada T]
通讯作者:
Yamada T
DOI:
10.1093/noajnl/vdad042
发表时间:
2023-01
期刊:
NEURO-ONCOLOGY ADVANCES
影响因子:
--
作者:
[Mander, Sunam, Gorman, Gregory S., Coward, Lori U., Christov, Konstantin, Green, Albert, Das Gupta, Tapas K., Yamada, Tohru]
通讯作者:
Yamada, Tohru
DOI:
10.3389/fonc.2022.940001
发表时间:
2022
期刊:
FRONTIERS IN ONCOLOGY
影响因子:
4.7
作者:
[Mander, Sunam, Naffouje, Samer A., Gao, Jin, Li, Weiguo, Christov, Konstantin, Green, Albert, Bongarzone, Ernesto R., Das Gupta, Tapas K., Yamada, Tohru]
通讯作者:
Yamada, Tohru
DOI:
10.3390/ijms241612931
发表时间:
2023-08-18
期刊:
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
影响因子:
5.6
作者:
[Nhan, Nguyen Thi Thanh, Yamada, Tohru, Yamada, Kaori H.]
通讯作者:
Yamada, Kaori H.
DOI:
10.1016/j.ebiom.2022.103850
发表时间:
2022-03
期刊:
EBioMedicine
影响因子:
11.1
作者:
[Goto M, Ryoo I, Naffouje S, Mander S, Christov K, Wang J, Green A, Shilkaitis A, Das Gupta TK, Yamada T]
通讯作者:
Yamada T
共 7 条
Intraoperative Imaging for Lymph Node Metastases
-
批准号:10646823
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2023
-
负责人:Tohru Yamada
-
依托单位:
Hypoxia-activated probiotic agents for breast cancer
-
批准号:10660233
-
项目类别:
-
资助金额:$38.08万
-
财政年份:2023
-
负责人:Tohru Yamada
-
依托单位:
MicroRNA Targeted Therapeutic Approach for Pediatric High-Grade Glioma
-
批准号:10043989
-
项目类别:
-
资助金额:$41.11万
-
财政年份:2020
-
负责人:Tohru Yamada
-
依托单位:
Development of a New Fluorescent Agent for Intraoperative Image-Guided Breast Cancer Surgery
-
批准号:9903292
-
项目类别:
-
资助金额:$35.98万
-
财政年份:2018
-
负责人:Tohru Yamada
-
依托单位:
海外基金